INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237801, 'Fenfluramine', 'Tetrabenazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245862/', '', 'Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Diethylpropion, Mazindol, Lacosamide', 'Dalfampridine, Tafamidis, Riluzole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237802, 'Tetrabenazine', 'Melatonin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245868/', '', 'Nitrazepam, Zopiclone', 'Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237803, 'Tetrabenazine', 'Methohexital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245869/', '', 'Nitrazepam, Zopiclone, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237804, 'Tetrabenazine', 'Ozanimod', 'Major', 'Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.  Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.  Advice from a cardiologist should be sought if treatment with ozanimod is considered in patients with significant QT prolongation (QTcF greater than 450 msec in males or 470 msec in females), patients on concurrent therapy with QT prolonging drugs with a known risk of torsades de pointes or drugs that slow heart rate or AV conduction, or in patients with arrhythmias requiring treatment with Class 1a or Class III antiarrhythmic agents.', 'Synergism', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245872/', '', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237805, 'Tetrabenazine', 'Pralsetinib', 'Moderate', 'Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245874/', '', 'Imatinib, Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More', 'Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237806, 'Tetrabenazine', 'Scopolamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245876/', '', 'Nitrazepam, Zopiclone, Ketorolac, Homatropine, Atropine, Ephedrine, Methscopolamine, Tropicamide, Phenylephrine, Aprepitant', 'Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237807, 'Bromocriptine', 'Telotristat ethyl', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bromocriptine.', 'DDInter', 'The potential for diminished pharmacologic effects of bromocriptine should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bromocriptine should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245884/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Tolcapone, Rotigotine, Pergolide, Pramipexole, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237808, 'Budesonide', 'Telotristat ethyl', 'Moderate', 'Concomitant use of orally and rectally administered formulations of budesonide with inducers of CYP450 3A4 may decrease budesonide systemic as well as local exposure at the gut mucosa.  Budesonide undergoes extensive first-pass and systemic metabolism via intestinal and hepatic CYP450 3A4', 'DDInter', 'The potential for diminished pharmacologic effects of orally and rectally administered budesonide should be considered during concomitant treatment with drugs that induce CYP450 3A4.  Alternative treatments or budesonide dose adjustments may be required if an interaction is suspected.', 'Metabolism, Absorption', 'The potential for diminished pharmacologic effects of orally and rectally administered budesonide should be considered during concomitant treatment with drugs that induce CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245885/', '', 'Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237809, 'Telotristat ethyl', 'Perampanel', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme.', 'DDInter', 'According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245904/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237810, 'Tramadol', 'Telotristat ethyl', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tramadol, which is primarily metabolized by CYP450 3A4 and 2D6.  Reduced opioid efficacy can occur, including opioid withdrawal in physically dependent patients.', 'DDInter', 'Caution is advised when tramadol is used with CYP450 3A4 inducers.  Patients should be monitored for opioid efficacy and signs of withdrawal.  If a CYP450 3A4 inducer is discontinued, monitor for seizures, serotonin syndrome, sedation, and respiratory depression.', 'Metabolism', 'Caution is advised when tramadol is used with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245911/', '', 'Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237811, 'Fidaxomicin', 'Rifaximin', 'Moderate', 'Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.', 'DDInter', 'Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245917/', '', 'Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Streptomycin, Rifaximin, Paromomycin, Neomycin', 'Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Paromomycin, Neomycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237812, 'Rifaximin', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.', 'DDInter', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism, Excretion', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245922/', '', 'Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More', 'Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Tetracycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237813, 'Selpercatinib', 'Rifaximin', 'Moderate', 'Coadministration with selpercatinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine, kidney, and/or liver due to inhibition of P-gp-mediated efflux by selpercatinib.', 'DDInter', 'Caution is advised when selpercatinib is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever selpercatinib is added to or withdrawn from therapy.', 'Metabolism, Absorption, Excretion', 'Caution is advised when selpercatinib is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245923/', '', 'Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Tetracycline, More', 'Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237814, 'Heparin (flush)', 'Drotrecogin alfa', 'Moderate', 'Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.', 'DDInter', 'Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.', 'Synergism', 'Caution and monitoring (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245930/', '', 'Acenocoumarol, Selexipag', 'Acenocoumarol, Selexipag, Drotrecogin alfa, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine, Nandrolone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237815, 'Drotrecogin alfa', 'Turmeric', 'Moderate', 'Turmeric may potentiate the bleeding risk associated with drugs that interfere with platelet function or coagulation.', 'DDInter', 'Caution is advised when turmeric-containing products are used concomitantly with drugs that affect hemostasis such as anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, serotonin reuptake inhibitors, and thrombolytic agents.  Clinical and laboratory observation for hematologic complications is recommended.', 'Synergism', 'Caution is advised when turmeric-containing products are used concomitantly with drugs that affect hemostasis such as anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, serotonin reuptake inhibitors, and thrombolytic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245936/', '', 'Protein C, Acenocoumarol, Selexipag', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237816, 'Triamcinolone (ophthalmic)', 'Bacillus calmette-guerin substrain tice live antigen', 'Moderate', 'The administration of live, attenuated virus or bacterial vaccines during corticosteroid therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive corticosteroid therapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored.  The interval depends on the dosage and duration of corticosteroid therapy administered, but may be at least 3 months in most cases.  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, high-dose corticosteroid therapy should not be initiated for at least 2 weeks.  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Synergism', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive corticosteroid therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245938/', '', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, Mupirocin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237817, 'Berotralstat', 'Triamcinolone (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme.  The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations.  Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy.  Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.  Some authorities advise against concomitant use unless the potential benefit outweighs the risk.  If the combination is considered necessary, a lower dosage of the corticosteroid may be required.  When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required.  Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders.  Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents.  Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.  Signs and symptoms of adrenal insufficiency include anorexia, hypoglycemia, nausea, vomiting, weight loss, muscle wasting, fatigue, weakness, dizziness, postural hypotension, depression, and adrenal crisis manifested as inability to respond to stress (e.g., illness, infection, surgery, trauma).', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245939/', '', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, Mupirocin, Mometasone furoate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237818, 'Yellow Fever Vaccine', 'Triamcinolone (ophthalmic)', 'Moderate', 'The administration of live, attenuated virus or bacterial vaccines during corticosteroid therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive corticosteroid therapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored.  The interval depends on the dosage and duration of corticosteroid therapy administered, but may be at least 3 months in most cases.  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, high-dose corticosteroid therapy should not be initiated for at least 2 weeks.  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Synergism', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive corticosteroid therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246005/', '', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, Mupirocin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237819, 'Varicella Zoster Vaccine (Recombinant)', 'Triamcinolone (ophthalmic)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, the U.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246006/', '', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, Mupirocin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237820, 'Radium Ra 223 dichloride', 'Aurothioglucose', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246008/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237821, 'Interferon alfa-2a, Recombinant', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246011/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237822, 'Interferon alfa-n1', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246012/', '', 'Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237823, 'Radium Ra 223 dichloride', 'Levamisole', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246013/', '', 'Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237824, 'Radium Ra 223 dichloride', 'Lisocabtagene maraleucel', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246014/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237825, 'Radium Ra 223 dichloride', 'Melphalan flufenamide', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246017/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237826, 'Radium Ra 223 dichloride', 'Naxitamab', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246019/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237827, 'Radium Ra 223 dichloride', 'Paramethadione', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246020/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237828, 'Radium Ra 223 dichloride', 'Phenylbutazone', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246021/', '', 'Acetylsalicylic acid, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237829, 'Radium Ra 223 dichloride', 'Plicamycin', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246022/', '', 'Valrubicin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237830, 'Radium Ra 223 dichloride', 'Promazine', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246023/', '', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237831, 'Sodium phosphate, monobasic (p32)', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246026/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237832, 'Tocainide', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246029/', '', 'Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237833, 'Tositumomab', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246030/', '', 'Iodide I-131', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237834, 'Trimethadione', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246031/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237835, 'Uracil mustard', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246033/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237836, 'Sodium oxybate', 'Scopolamine', 'Major', 'The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects.', 'DDInter', 'Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.  Otherwise, close monitoring and/or dosage reductions should be considered.  If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.  All patients treated with sodium oxybate should be advised not to drive, operate machinery, or engage in potentially hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking the second nightly dose of sodium oxybate and until they know how the medication affects them.', 'Synergism', 'Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246048/', '', 'Amobarbital, Melatonin, Nitrazepam, Zopiclone, Ketorolac, Homatropine, Atropine, Ephedrine, Methscopolamine, Tropicamide, Phenylephrine, More', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate, Dalfampridine, Riluzole, Inotersen, Pitolisant, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237837, 'Abarelix', 'Sparfloxacin', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246050/', '', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237838, 'Sparfloxacin', 'Acetohexamide', 'Major', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.', 'Others', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246051/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Enoxacin, Lomefloxacin, Grepafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237839, 'Aminolevulinic acid', 'Sparfloxacin', 'Major', 'Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.', 'DDInter', 'Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John''s wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid.  Some authorities recommend avoiding exposure to any photosensitizing agent for up to 2 weeks after oral administration of aminolevulinic acid, if possible.  Patients should also avoid exposure of the eyes and skin to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 48 hours after receiving aminolevulinic acid.', 'Synergism', 'Photosensitizing agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246053/', '', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More', 'Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237840, 'Anisindione', 'Sparfloxacin', 'Major', 'Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants.  The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.', 'DDInter', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.  The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.', 'Synergism', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246054/', '', 'Enoxacin, Delafloxacin, Lomefloxacin, Grepafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237841, 'Sparfloxacin', 'Astemizole', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246056/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Enoxacin, Nalidixic acid, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237842, 'Sparfloxacin', 'Attapulgite', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246057/', '', 'Pectin, Activated charcoal', 'Enoxacin, Lomefloxacin, Grepafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237843, 'Sparfloxacin', 'Axicabtagene ciloleucel', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246058/', '', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More', 'Enoxacin, Lomefloxacin, Grepafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237844, 'Bepridil', 'Sparfloxacin', 'Major', 'Quinolones such as ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.', 'DDInter', 'Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, as well as bepridil.', 'Synergism', 'Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246060/', '', 'Enoxacin, Nalidixic acid, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237845, 'Bifidobacterium longum infantis', 'Sparfloxacin', 'Moderate', 'Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.', 'DDInter', 'Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246062/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237846, 'Brexucabtagene autoleucel', 'Sparfloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246064/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237847, 'Bromfenac', 'Sparfloxacin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246065/', '', 'Fluocinolone acetonide, Fluorometholone', 'Enoxacin, Lomefloxacin, Grepafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237848, 'Calcium glycerophosphate', 'Sparfloxacin', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246066/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237849, 'Chromium picolinate', 'Sparfloxacin', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246068/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237850, 'Cisapride', 'Sparfloxacin', 'Major', 'Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246070/', '', 'Metoclopramide', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237851, 'Copper gluconate', 'Sparfloxacin', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246071/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237852, 'Dicoumarol', 'Sparfloxacin', 'Major', 'Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants.  The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.', 'DDInter', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.  The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.', 'Synergism', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246073/', '', 'Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More', 'Enoxacin, Delafloxacin, Lomefloxacin, Grepafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237853, 'Halofantrine', 'Sparfloxacin', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246077/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237854, 'Insulin human', 'Sparfloxacin', 'Major', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.', 'Others', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246079/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237855, 'Insulin aspart (aspart protamine)', 'Sparfloxacin', 'Major', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.', 'Others', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246080/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237856, 'Insulin lispro (protamine)', 'Sparfloxacin', 'Major', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.', 'Others', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246081/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237857, 'Iron protein succinylate', 'Sparfloxacin', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246084/', '', 'Iron sucrose, Cyanocobalamin, Folic acid', 'Enoxacin, Lomefloxacin, Grepafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237858, 'Isoetharine', 'Sparfloxacin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246085/', '', 'Enoxacin, Nalidixic acid, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237859, 'Sparfloxacin', 'Ketoconazole', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246086/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237860, 'Sparfloxacin', 'Levacetylmethadol', 'Major', 'Levomethadyl acetate may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246091/', '', 'Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine', 'Enoxacin, Nalidixic acid, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237861, 'Sparfloxacin', 'Lisocabtagene maraleucel', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246092/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237862, 'Sparfloxacin', 'Magaldrate', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246093/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237863, 'Sparfloxacin', 'Magnesium glycinate', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246096/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237864, 'Sparfloxacin', 'Melphalan flufenamide', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246100/', '', 'Bendamustine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237865, 'Sparfloxacin', 'Methotrimeprazine', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246101/', '', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Enoxacin, Nalidixic acid, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237866, 'Sparfloxacin', 'Phenolphthalein', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246109/', '', 'Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More', 'Enoxacin, Nalidixic acid, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237867, 'Sparfloxacin', 'Phenylbutazone', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246110/', '', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide', 'Enoxacin, Lomefloxacin, Grepafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237868, 'Sparfloxacin', 'Plicamycin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246112/', '', 'Ixabepilone, Valrubicin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237869, 'Sparfloxacin', 'Pralsetinib', 'Moderate', 'Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246114/', '', 'Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, More', 'Enoxacin, Trovafloxacin, Nalidixic acid, Cinoxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237870, 'Sparfloxacin', 'Probucol', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246115/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237871, 'Sparfloxacin', 'Promazine', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246116/', '', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Enoxacin, Nalidixic acid, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237872, 'Sparfloxacin', 'Relugolix', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246117/', '', 'Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237873, 'Sparfloxacin', 'Ritodrine', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.  It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246118/', '', 'Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237874, 'Sparfloxacin', 'Rofecoxib', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246119/', '', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237875, 'Sparfloxacin', 'Sacituzumab govitecan', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246120/', '', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237876, 'Tacrine', 'Sparfloxacin', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%).', 'DDInter', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.  Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246124/', '', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 'Memantine, Aducanumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237877, 'Terfenadine', 'Sparfloxacin', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246127/', '', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237878, 'Triflupromazine', 'Sparfloxacin', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246129/', '', 'Enoxacin, Nalidixic acid, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237879, 'Alimemazine', 'Sparfloxacin', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246130/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Enoxacin, Nalidixic acid, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237880, 'Troglitazone', 'Sparfloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.', 'Others', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246131/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237881, 'Uracil mustard', 'Sparfloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246132/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', 'Bendamustine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237882, 'Valdecoxib', 'Sparfloxacin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246133/', '', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237883, 'Acrivastine', 'Zaleplon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246136/', '', 'Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237884, 'Chlorcyclizine', 'Zaleplon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246141/', '', 'Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine', 'Temazepam, Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Amobarbital, Meprobamate, Butalbital, Eszopiclone, Estazolam, Methylphenobarbital, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237885, 'Dimenhydrinate', 'Zaleplon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246144/', '', 'Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237886, 'Estazolam', 'Zaleplon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246146/', '', 'Nitrazepam, Thiopental, Paraldehyde, Amobarbital, Ethchlorvynol, Pentobarbital, Zaleplon, Dichloralphenazone', 'Estazolam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237887, 'Fenfluramine', 'Zaleplon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246147/', '', 'Dexfenfluramine, Naltrexone, Ephedrine, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Rufinamide', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237888, 'Flurazepam', 'Zaleplon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246148/', '', 'Nitrazepam, Thiopental, Paraldehyde, Amobarbital, Ethchlorvynol, Pentobarbital, Zaleplon, Dichloralphenazone', 'Thiopental, Nitrazepam, Zopiclone, Flurazepam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237889, 'Halazepam', 'Zaleplon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246151/', '', 'Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237890, 'Zaleplon', 'Levodopa', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246153/', '', 'Amantadine, Cabergoline', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237891, 'Zaleplon', 'Methohexital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246155/', '', 'Nitrazepam, Thiopental, Paraldehyde, Amobarbital, Ethchlorvynol, Pentobarbital, Zaleplon, Dichloralphenazone, Halothane, Thiopental, Isoflurane, More', 'Nitrazepam, Zopiclone, Methohexital', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237892, 'Zaleplon', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', 'DDInter', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246160/', '', 'Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 'Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237893, 'Zaleplon', 'Scopolamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246163/', '', 'Nitrazepam, Thiopental, Paraldehyde, Amobarbital, Ethchlorvynol, Pentobarbital, Zaleplon, Dichloralphenazone, Homatropine, Atropine, Ephedrine, More', 'Scopolamine, Nitrazepam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237894, 'Zaleplon', 'Selegiline', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246164/', '', 'Amantadine, Cabergoline', 'Nitrazepam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237895, 'Aflibercept', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246167/', '', 'Bevacizumab, Verteporfin, Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237896, 'Aflibercept', 'Yellow Fever Vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246223/', '', 'Bevacizumab, Verteporfin, Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237897, 'Aflibercept', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, the U.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246224/', '', 'Bevacizumab, Verteporfin, Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237898, 'Streptozocin', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246226/', '', 'Uracil mustard', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237899, 'Ibritumomab tiuxetan', 'Streptozocin', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', 'DDInter', 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246234/', '', 'Tositumomab, Iodide I-131', 'Uracil mustard', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237900, 'Streptozocin', 'Melphalan flufenamide', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', 'DDInter', 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/246246/', '', 'Streptozocin, Uracil mustard', 'Melphalan, Melphalan flufenamide, Uracil mustard', 1767369485);
